PROMs in reimbursement and real-world assessments of clinical interventions Stirling Bryan, PhD.

Slides:



Advertisements
Similar presentations
Translating Evidence into Practice Danny Liew Melbourne EpiCentre Medical Unit 1.
Advertisements

Donald T. Simeon Caribbean Health Research Council
©PPRNet 2014 Impact of Patient Engagement on Treatment Decisions and Patient-Centered Outcomes in the Implementation of New Guidelines for the Treatment.
99.98% of the time patients are on their own “The diabetes self-management regimen is one of the most challenging of any for chronic illness.” 0.02% of.
Kat Smithson Policy and Campaigns Manager, NAT HIV prevention in England’s high prevalence local authorities: 2013/ /15 February 2015.
Public Health Perspective on Radon Control in Ireland Dr. Ina Kelly Specialist Registrar in Public Health Medicine Health Service Executive Department.
©PPRNet 2014 Impact of Patient Engagement on Treatment Decisions and Patient-Centered Outcomes in the Implementation of New Guidelines for the Treatment.
Is it time to ban PSA? In support of OFSA… Stirling Bryan, PhD.
In Search of Efficiency, Consistency, Fairness, and Impact in HTA: The Case for Clinical Pathway Management and Modelling Stirling Bryan, PhD Graham Scotland,
SEBs: “What do patients say? Presented by Cheryl L. Koehn 2015 CADTH Symposium Saskatoon, Saskatchewan April 14, 2015.
Economic Analysis and Management Todd Wagner, PhD.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. February 25, 2009.
CADTH Therapeutic Reviews
David Tyas Global HEOR - Lundbeck
Journal Club Alcohol and Health: Current Evidence March-April 2006.
Clinical trials methodology group Simon Gates 9 February 2006.
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Economic evaluation of outcomes: long term primary and surrogate endpoints Dr. Giampiero Favato presented at the University Program in Health Economics.
Making Cost Effectiveness Analyses more useful: Budget Impact Curves Christopher McCabe PhD Endowed Research Chair in Emergency Medicine Research University.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
Measuring and valuing health outcome Montarat Thavorncharoensap, Ph.D. 1: Faculty of Pharmacy, Mahidol University 2. HITAP, Thailand.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
©The Work Foundation Stephen Bevan Director, Centre for Workforce Effectiveness The Work Foundation & Honorary Professor Lancaster University The Clinical.
NICE Decision Making Dr Katherine Payne North West Genetics Knowledge Park The University of Manchester
Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.
My Own Health Report: Case Study for Pragmatic Research Marcia Ory Texas A&M Health Science Center Presentation at: CPRRN Annual Grantee Meeting October.
Electronic Health Records and Clinical Decision Support Systems Impact on National Ambulatory Care Quality Max J. Romano, BA; Randall S. Stafford, MD,
Clinical Pharmacy Part 2
Introduction to MAST Kristian Kidholm Odense University Hospital, Denmark.
XXX_DECRIPT_MON00/1 Quality and impact of Social Science and Operations Research by the Special Programme in Human Reproduction Department of Reproductive.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
HERU is supported by the Chief Scientist Office of the Scottish Executive Health Department. The author accepts full responsibility for this talk. Economic.
National Perspective Cancer Early Detection & Prevention Performance Review Event October 2008 National Cancer Action Team Kathy Elliott National Lead.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
Cancer Mortality Target Measuring and Monitoring at a National Level Jennifer Benjamin, Department of Health Kathy Elliott, National Cancer Action Team.
Promoting high quality, cost effective drug therapy throughout the Military Health System Identification and Use of Published Health Economic Evaluations.
Comparative Effectiveness Research : Rethinking Therapeutic Evaluation in Chronic Diseases Ph Ravaud.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Intermittent vs Continuous Pulse Oximetry McCulloh R, Koster M, Ralston S, et al.
Workshop 18 th May 2010, Brussels Applying the Value+ model on patient involvement in HTA processes.
1 Dissemination and Implementation Paul K. Whelton MD, MSc for the ALLHAT Collaborative Research Group ALLHAT U.S. Department of Health and Human Services.
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
BEST PRACTICE PORTAL BEST PRACTICE PORTAL project presentation to the Scientific Committee Ferri et al Lisbon, 16th July 2010.
HTA Efficient Study Designs Peter Davidson Head of HTA at NETSCC.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
The Value of Reference Case Methods for Resource Allocation Decision Making Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics.
The contribution of PROMs to health care sustainability Mark Harrison Stirling Bryan Deborah Marshall Nick Bansback.
Presentation Developed for the Academy of Managed Care Pharmacy
Focus on health and care of mothers and infants ChiMat conference, 2009 Professor Mary Renfrew Mother and Infant Research Unit.
Economics of Complementary and Integrative Medicine: Where Do We Go From Here? Patricia M. Herman, ND, PhD, RAND Corporation IM4US Boston August 8, 2014.
School of Population and Public Health PROMs to support informed patient decision making Nick Bansback, PhD Assistant Professor School of Population and.
Cancer Drug Funding Sustainability: From Recommendations to Action CADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs.
‘Enhancing musculoskeletal research in primary care: engaging a community musculoskeletal physiotherapy service in research studies’ Presented by : Carol.
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Continuous Improvement & Real World Evidence: A Public Payer’s Perspective Suzanne McGurn, Assistant Deputy Minister and Executive Officer Ontario Public.
Kingdom of Bahrain Dr. Naeema Isa Al Sabaeei 2014
Variation in health state preferences across local and international populations: East doesn’t meet West CADTH symposium Panel Session April 12, 2016.
Musculoskeletal Health in Europe
Towards UK poSt Arthroplasty Follow-up rEcommendations: UK SAFE
Health care decision making
Assessing value for money: principles, methods and issues
Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:
Regulatory Perspective of the Use of EHRs in RCTs
Incremental Cost-Effectiveness Ratio (ICER) exponentially decreases as the duration of wear increases. Incremental Cost-Effectiveness Ratio (ICER) exponentially.
Evidence-Based Public Health
Introduction to Health Economics (1)
Cost-effectiveness acceptability frontier for three risk-assessment strategies related to pressure-injury prevention best practices from a US societal.
Nutrition Interventions to Improve Quality of Care
Stirling Bryan, PhD Scientific Director, BC SUPPORT Unit
Presentation transcript:

PROMs in reimbursement and real-world assessments of clinical interventions Stirling Bryan, PhD

2 Disclosures Some of my relevant current activities: –Director, Centre for Clinical Epidemiology & Evaluation, Vancouver Coastal Health Research Institute –Chair, CADTH’s Health Technology Expert Review Panel –Member, BC’s Health Technology Assessment Committee –Member, EuroQol Group My Centre has a contract to conduct HTA projects for the BC Ministry of Health. I am not aware of any other actual or potential conflicts of interest in relation to this presentation.

3 Overview of talk Example PROMs PROMs in support of HTA Moving from HTA to health technology management (HTM) PROMs in support of HTM

4 Generic utility-based PROMs Short Form Health Survey instruments EQ-5D

5 Whitehead S J, Ali S Br Med Bull 2010;96:5-21 PROMs give us Quality-Adjusted Life Years (QALYs)

6 Example Markov model

7 CEA / CUA results “Riluzole is recommended for the treatment of individuals with amyotrophic lateral sclerosis (ALS) form of Motor Neurone Disease (MND).”

8 Cost-effectiveness plane Drummond, et al Methods for the economic evaluation of health care programmes: Oxford University Press

9

10

11 MOVING FROM HTA TO HEALTH TECHNOLOGY MANAGEMENT

12

13 Areas of concern Primary concern: The ‘performance’ of health technologies in routine use (1)Model validation questions: How good are our models? Are the predicted benefits and costs really delivered? (2)Improvement questions: Can we get better value from existing technologies? (3)Appropriateness questions: Do we see indication creep? (e.g., Statins for primary prevention in low-risk patients) (4)Withdrawal questions: Are technologies nearing the end of their useful life?

14 Copyright ©2005 BMJ Publishing Group Ltd. Miners, A H et al. BMJ 2005;330:65 Logged pairwise comparison of incremental cost effectiveness ratios

15 Michael Fish and the Great Storm of “The Great Storm of 1987 occurred on the night of 15–16 October 1987, when an unusually strong weather system caused winds to hit much of southern England and northern France. It was the worst storm to hit England since the Great Storm of 1703 (284 years earlier) and was responsible for the deaths of at least 22 people in England and France.” But what did the BBC weather forecaster say? Wikipedia

16 Areas of concern Primary concern: The ‘performance’ of health technologies in routine use (1)Model validation questions: How good are our models? Are the predicted benefits and costs really delivered? (2)Improvement questions: Can we get better value from existing technologies? (3)Appropriateness questions: Do we see indication creep? (4)Withdrawal questions: Are technologies nearing the end of their useful life?

17 Technology management

18 Technology management examples Knee arthroplasty: –20% of patients ‘dissatisfied’, many with ongoing poor outcomes Asthma: –we have highly effective low cost therapies that people don’t use Rheumatoid Arthritis: –recent evidence suggests high cost biological treatment not superior to conventional therapy

19 HTA and HTM Life-cycle evaluation of health technologies –Data systems (including PROMs) to facilitate monitoring of technologies in use –In part to validate analysis predictions made at the time of coverage/reimbursement Early HTAAdoptionOngoing assessment DisinvestmentAppropriate Use

20

21 A pan-Canadian HTM Strategy? CADTH leading this work Pan-Canadian HTM agenda (input from all jurisdictions) Consideration of overall system impact (including clinical guidelines, health human resources, fee codes) Common processes for new and in-use technologies Post-market surveillance programs (incorporating real world evidence) Enhanced knowledge mobilization

22